I am co-founder of NanoProx, a startup developing bismuth-based nanoparticles to improve radiotherapy in oncology. My work focuses on bridging nanotechnology and cancer treatment, with the goal of developing more effective and precise therapeutic approaches.My scientific background is in the synthesis of bismuth-based nanomaterials, and I have been especially interested in how these materials can be engineered for biomedical applications with real translational potential. Over time, this interest evolved from fundamental materials research into a broader commitment to developing technologies that can address unmet needs in cancer care.At NanoProx, I work at the intersection of nanotechnology, oncology, and innovation. What motivates me most is the possibility of turning advances in materials science into practical tools that can strengthen radiotherapy and ultimately improve patient outcomes. I am particularly passionate about building solutions that combine strong scientific foundations with a clear clinical purpose.